Kolltan Pharmaceuticals

About:

Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.

Website: http://www.kolltan.com

Twitter/X: arthurajr

Top Investors: Fidelity, Deerfield, Purdue Pharma, OUP (Osage University Partners), HBM Healthcare Investments

Description:

Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.